Corporate Banner
Satellite Banner
Technology Networks Header
Friday, July 25, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Cyprotex Introduces Genomic ADME Service
Friday, December 09, 2011
Cyprotex plc now provides the service, which can provide researchers with actionable data about genomic differences in drug response at the early stages of drug development.

New Sorbent is Designed and Tested for Drugs of Abuse Extraction in Forensic Toxicology
Wednesday, January 19, 2011
Phenomenex Inc. have introduced Strata™-X-Drug B, a new solid phase extraction (SPE) sorbent specially designed and quality-control tested for drugs of abuse. Strata-X-Drug B, a polymeric strong cation-exchange SPE sorbent, does not require conditioning, saving time and solvent expense.

<< 1 2 3 4 5 6 7 >>
Showing Results 61 - 62 of 62
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv